Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: Results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial
The Journal of Allergy and Clinical Immunology: In Practice | Nov 03, 2017
The Journal of Allergy and Clinical Immunology: In Practice | Nov 03, 2017